PMID- 20689997
OWN - NLM
STAT- MEDLINE
DCOM- 20110420
LR  - 20211203
IS  - 1776-260X (Electronic)
IS  - 1776-2596 (Linking)
VI  - 5
IP  - 2
DP  - 2010 Jun
TI  - Perspectives in drug development for metastatic renal cell cancer.
PG  - 139-56
LID - 10.1007/s11523-010-0149-2 [doi]
AB  - Patients with renal cell carcinoma (RCC) exhibit a spectrum of clinical outcomes, 
      with some patients following an indolent clinical course and others displaying 
      rapidly advancing disease. As evidence points to RCC being largely refractory to 
      traditional chemotherapy and radiotherapy strategies, immunotherapeutic 
      approaches played a dominant role in the management of metastatic RCC for a 
      quarter of a century. Management of this challenging tumor has been 
      revolutionized by the incorporation of molecularly targeted therapies such as 
      inhibitors of pathways involving tyrosine kinase signaling and the mammalian 
      target of rapamycin (mTOR). The improvements in disease stabilization and 
      survival seen with these agents has meant that molecularly targeted therapy now 
      forms the foundation for treating RCC and has resulted in a multitude of studies 
      investigating similar compounds for efficacy in RCC. Despite this, the rationale 
      for using immunomodulatory regimens remains strong and its ongoing place in this 
      era of targeted treatments continues to pose interesting clinical questions. The 
      challenge of maintaining durable responses from our current therapies persists 
      and this review highlights the plethora of options now available in RCC treatment 
      and the directions in which modern management are heading.
FAU - Basu, Bristi
AU  - Basu B
AD  - University Department of Oncology, Addenbrooke's Hospital, University of 
      Cambridge, Cambridge, CB2 2QQ, UK. Bristi.basu@cancer.org.uk
FAU - Eisen, Tim
AU  - Eisen T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20100806
PL  - France
TA  - Target Oncol
JT  - Targeted oncology
JID - 101270595
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Antineoplastic Protocols
MH  - Carcinoma, Renal Cell/*drug therapy/immunology/pathology/physiopathology
MH  - Clinical Trials as Topic
MH  - Disease Progression
MH  - Drug Discovery/trends
MH  - Humans
MH  - *Immunotherapy
MH  - Kidney Neoplasms/*drug therapy/immunology/pathology/physiopathology
MH  - Neoplasm Metastasis
MH  - Protein-Tyrosine Kinases/antagonists & inhibitors
MH  - Signal Transduction/drug effects
MH  - TOR Serine-Threonine Kinases/therapeutic use
MH  - Treatment Outcome
EDAT- 2010/08/07 06:00
MHDA- 2011/04/22 06:00
CRDT- 2010/08/07 06:00
PHST- 2010/05/16 00:00 [received]
PHST- 2010/07/12 00:00 [accepted]
PHST- 2010/08/07 06:00 [entrez]
PHST- 2010/08/07 06:00 [pubmed]
PHST- 2011/04/22 06:00 [medline]
AID - 10.1007/s11523-010-0149-2 [doi]
PST - ppublish
SO  - Target Oncol. 2010 Jun;5(2):139-56. doi: 10.1007/s11523-010-0149-2. Epub 2010 Aug 
      6.